Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039916 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT07039916 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 231 participants, above the 122-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT07039916, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
California
- Site Number - 1010 - Carlsbad
- Site Number - 1028 - Irvine
- Site Number - 1023 - Los Angeles
- Site Number - 1029 - Rancho Mirage
- Site Number - 1004 - San Francisco
Florida
- Site Number - 1006 - Clearwater
- Site Number - 1037 - Ormond Beach
- Site Number - 1002 - Port Charlotte
- Site Number - 1050 - Rockledge
- Site Number - 1007 - Tampa
Arizona
- Site Number - 1017 - Phoenix
- Site Number - 1025 - Scottsdale
- Site Number - 1042 - Tucson
Georgia
- Site Number - 1014 - Atlanta
- Site Number - 1043 - Augusta
Alabama
- Site Number - 1041 - Mobile
Colorado
- Site Number - 1027 - Fort Collins
Connecticut
- Site Number - 1001 - New Haven
District of Columbia
- Site Number - 1024 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07039916
The ClinicalTrials.gov registry entry for NCT07039916 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (89% higher). The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07039916 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07039916 about?
NCT07039916 is a clinical study titled "Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis". The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
What is the current status of trial NCT07039916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2025-05-27. Estimated completion is 2028-12.
What conditions does trial NCT07039916 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT07039916?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT07039916?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07039916 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.